All News

In predicting PCSM at 10 years, the area under the curve with the P-score was 0.93, compared with 0.81 with D’Amico and 0.88 with CAPRA.

Patients in the CONTACT-02 trial were randomly assigned 1:1 to receive cabozantinib plus atezolizumab or a second novel hormonal therapy of either abiraterone and prednisone or enzalutamide.

A multidisciplinary team at the Vanderbilt Institute for Surgery and Engineering is collaborating on a 3D navigational system to help limit kidney stone fragments that remain after surgery.

Laura Bukavina, MD, MPH, highlights a BCAN Think Tank session on real-world applications of microbiome in bladder cancer.

The Northwestern Medicine Department of Urology provides no-cost continuing medical education programs for urology professionals.

Use of non-contrast MRI also showed the potential to decrease identification of clinically insignificant disease.

Patients in the phase 3 LITESPARK-005 trial were randomized to belzutifan or everolimus after receiving both a PD-1/L1 inhibitor and a VEGF-TKI for their renal cell carcinoma.

In this interview, Yair Lotan, MD, discusses the steps needed for urine biomarkers to be incorporated into standard clinical practice in bladder cancer management.

Last year, a single health care breach involved 2 million records, but in the first half of 2023, there were 5 health care breaches of at least 3 million records each.

The incidence of 12-month surgical repair failure was 19% among those who received vaginal estrogen, compared with 9% among those who received placebo.

The prospective, open-label, phase 2 SOLAR study enrolled 26 patients with metastatic prostate cancer.

The study assessed MG-AGEs, SRAGE, GLO1, and AGER, 4 biomarkers that are associated with methyglyoxal.

"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.

Approximately half of prostate cancer patients with clinically actionable gene variants do not meet the NCCN guideline criteria for genetic testing, according to findings from the PROCLAIM trial.

The new drug application is supported by findings from the phase 3 CERTAIN-1 trial.

“The results of the current study indicate that 100% of the elderly patients who were referred for PSMA PET/CT on the basis of clinical suspicion only were found to have avid disease," said Einat Even-Sapir, MD, PhD.

The FoundationOne CDx test will identify patients who are eligible to receive niraparib plus abiraterone based on the genomic profile of their prostate tumor.

"The next-generation Optilume BPH Catheter System offers a safe and effective new, minimally invasive treatment for BPH, reducing urinary obstruction with a low rate of sexual or other adverse effects," says Steven A. Kaplan, MD.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

The approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.

The SECURE trial exploring 64Cu/67Cu SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer has advanced to the highest dose level.

A total of 158 patients with NMIBC including tumors with stage carcinoma in situ, Ta, and T1 were enrolled in the prospective trial in mainland China.

The urine-based assay measures the expression of HOXC6 and DLX1 to determine whether a patient may benefit from prostate biopsy.

A recent study suggests that combined use of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy may be more effective for detecting clinically significant prostate cancers than using systematic biopsies alone

The novel test was developed and validated using the biomarkers Appl1, Sortilin, and Syndecan-1 that were studied by investigators at the University of South Australia.

The studies explored the use of opioids following surgery as well as the risk of incisional hernia.

"In patients with prostate cancer considered for surgery, PSMA-PET can provide information on the risk of recurrence after surgery, before the surgery even happens," says Loïc Djaïleb, MD, PhD.

Doctors and medical practices are mired in administrative tasks.

"The study revealed that the anatomical changes in the male pelvis could potentially favor the upright position for prostate treatments,” says Niek Schreuder.

The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.